Skip to content

Press Releases

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

Immunexpress.com

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration with the Molecular Diagnosis and…

Read More

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress.com

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent compliments the U.S. herpes virus…

Read More

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

Immunexpress.com

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD $982,707 grant will support the…

Read More

Immunexpress to Present Data on Utility of SeptiCyte™ LAB for Diagnosing Sepsis at the Pathology Diagnostics Conference

Immunexpress.com

Immunexpress to Present Data on Utility of SeptiCyte™ Lab for Diagnosing Sepsis at the Pathology Diagnostics Conference SeptiCyte™ Lab Quantifies Host Molecular Markers to Aid Physicians in the Diagnosis of Sepsis in Critical Care Patients SEATTLE, June 4, 2015 – Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical Affairs, will present data at…

Read More

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte™ LAB at the Next Generation Diagnostics Summit

Immunexpress.com

SEATTLE, Aug. 12, 2015 – Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in Washington, D.C. The presentation will…

Read More

Immunexpress Supports World Sepsis Day 2015

Immunexpress.com

Call for Action on Sept. 13 Includes Awareness, Education and Funding Initiatives to Help Reverse Global Increase in Numbers of Deaths from Sepsis    Video Interviews on the Immunexpress Website Highlight the Need for Faster Diagnosis of Sepsis  SEATTLE, Sept. 10, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected…

Read More

Immunexpress Presents Results Indicating the Utility of SeptiCyte™ for the Diagnosis of Sepsis in Critically Ill Children at the 45th Annual Society of Critical Care Medicine Congress

Immunexpress.com

Additional Results from the VENUS A Study Further Validate SeptiCyte as a Diagnostic Assay for Sepsis in Critically Ill Adults SEATTLE, Feb. 22, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data on the utility of SeptiCyte™ LAB in both adult and…

Read More

Immunexpress Announces Presentations at the 45th Annual Society of Critical Care Medicine Congress on the Utility of SeptiCyte™ LAB

Immunexpress.com

SEATTLE, Feb. 10, 2016 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data on the utility of SeptiCyte® Lab in both adult and pediatric populations to aid in the clinical assessment of sepsis in critical care patients will be presented at the upcoming 45th Annual…

Read More

Immunexpress Strengthens Board of Directors with Key Appointments

Immunexpress.com

Accomplished Industry Leaders Join Recently Appointed CEO, Dr. Rolland Carlson, to Expand on the Comprehensive Experience of the Board SEATTLE, May 15, 2018 /PRNewswire/ — Immunexpress, Inc. today announced the appointment of three new members to its Board of Directors. Rolland Carlson, PhD, Tanja Dowe and Katleen Verleysen, PhD, have joined the company’s board, while Bea Arnold, PhD, has stepped down from the board after…

Read More

Immunexpress Releases Key Performance Data on SeptiCyte™ LAB in PLOS Medicine Publication

Immunexpress.com

SEATTLE, Dec. 8, 2015 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today the publication of the discovery and validation of the SeptiCyte® Lab test for sepsis in PLOS Medicine. SeptiCyte® Lab is a rapid molecular assay that measures a patient’s gene expression level to differentiate between sepsis…

Read More
Scroll To Top